Clinical Courses and Prognostic Factors in Small Cell Lung Cancer.
- Author:
Dae Young ZANG
1
;
Jung Shin LEE
;
Tae Won KIM
;
Byung Hak JUNG
;
Hwan Jung YUN
;
Jong Soo CHOI
;
Jin Hee PARK
;
Dong Sook LEE
;
Je Hwan LEE
;
Sung Bae KIM
;
Sang We KIM
;
Cheol Won SUH
;
Kyoo Hyung LEE
;
Woo Kun KIM
;
Sang Hee KIM
Author Information
1. Department of Medicine, Asan Medical Center, School of Medicine, University of Ulsan, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Small cell lung cancer;
Prognosis;
Treatment response;
Survival
- MeSH:
Alkaline Phosphatase;
Disease-Free Survival;
Drug Therapy;
Follow-Up Studies;
Humans;
Male;
Natural History;
Prognosis;
Radiotherapy;
Recurrence;
Retrospective Studies;
Small Cell Lung Carcinoma*;
Survivors;
Thorax
- From:Korean Journal of Medicine
1998;54(1):90-100
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Although small cell lung cancer is a chemosensitive disease, it grows rapidly and relapses frequently. Even with optimum treatment, only small portion of patients have experienced long-term survival. The objective of this study was to describe the clinical characteristics and therapeutic features, and to analyze the prognosis in small cell lung cancer. METHODS: We analyzed retrospectively 151 evaluable patients with histologically confirmed small cell lung cancer from August 1989 to June 1995 at our institution. Of 151 patients, 3 had surgery and chemotherapy, 59 had chemotherapy and chest irradiation, and 89 had chemotherapy only. RESULTS: Most patients(82.1%) were men, and the median age was 62 years. Of all patients, 49% had performance status of 0,1 and 59.6% had limited disease. The overall response rate was 67.8% : complete response 23.8%, partial response 44.4%. Complete responses were documented in all of three patients who had surgery and chemotherapy, 49.2% of those who had chemotherapy and radiotherapy, and 4.5% of those who had chemotherapy only. The median follow-up duration was 309 days. The median progression-free survival and overall survival were 256 days and 354 days, respectively: patients who had surgery and chemotherapy were 1631 days and 1631 days, those who had chemotherapy and radiotherapy were 344 days and 450 days, and those who had chemotherapy only were 186 days and 278 days, respectively; complete responders were 580 days and 710 days, partial responders were 231 days and 364 days, non-responders were 132 days and 151 days, respectively. Of 151 patients, 11.3% survived more than two years(long-term survival). Most long-term survivors had limited disease(82.4%) and good performance(76.5%). Long-term survival occurred in two patients of those who had surgery and chemotherapy, 16.9% of those who had chemotherapy and radiotherapy, and 5.6% of those who had chemotherapy only. Most long-term survivors(70.6%) had complete response. Twenty of 36 complete responders and 8 of 17 long-term survivors had disease relapses or progressions. Patients with limited disease, those with good performance, and those with normal alkaline phosphatase had a significantly higher complete response rate and longer progression-free survival and overall survival than their counterparts. Of pretreatment characteristics, stage and performance status were correlated complete response and survival, independently. complete response outcome was significant independent variable for survival. CONCLUSION: The disappointing results in this disease support the need for both new treatment strategies to improve complete response rate and to decrease relapse rate and large-scaled prospective studies to know natural history of long-term survivors.
